Castle Biosciences, Inc.

Overview

1. "How the company got here" Castle Biosciences was founded in 2008 with the goal of improving patient care by developing innovative tests that could better predict disease outcomes. The company's early growth was fueled by its focus on developing decision-support tests for melanoma, a type of skin cancer. In 2019, Castle Biosciences became a publicly traded company, which provided it with capital to expand its operations and product offerings. The company further diversified its business by acquiring assets in gastroenterology in 2021 and expanding into mental health pharmacogenomics in 2022. 2. "What it actually does" Castle Biosciences is a molecular diagnostics company that creates specialized tests to help doctors make more informed decisions about patient care. These tests analyze a patient's biological information, often at the genetic level (gene expression profile or GEP), to predict the risk of disease progression, recurrence, or metastasis. The company's primary focus is on diseases where there's a high degree of uncertainty in diagnosis or treatment, aiming to provide personalized insights that can lead to better patient outcomes and more efficient healthcare. 3. "Dermatologic Oncology" This business line focuses on tests for skin cancers, with a significant emphasis on melanoma. The DecisionDx-Melanoma test, for example, uses a patient's tumor biology to predict the likelihood of metastasis (the spread of cancer) or recurrence, helping doctors decide on the intensity of follow-up care or if further procedures like sentinel lymph node biopsy are needed. Castle also offers tests for cutaneous squamous cell carcinoma (DecisionDx-SCC), another type of skin cancer, to help predict metastasis and recurrence risk, and for uveal melanoma (DecisionDx-UM), a rare eye cancer, to assess the risk of metastasis. Additionally, MyPath Melanoma helps diagnose ambiguous skin lesions. 4. "Gastroenterology" Within this segment, Castle Biosciences offers the TissueCypher Barrett's Esophagus test. This test is designed for patients with Barrett's esophagus, a condition where the lining of the esophagus changes and can increase the risk of developing esophageal cancer. The TissueCypher test helps predict a patient's individual risk of progressing to esophageal cancer, allowing doctors to make more informed decisions about monitoring and management. 5. "Atopic Dermatitis" Castle Biosciences has developed the AdvanceAD-Tx test, which is a gene expression profile (GEP) test aimed at guiding treatment decisions for patients with moderate to severe atopic dermatitis (eczema). This test helps physicians determine the most appropriate systemic treatment for a patient, potentially avoiding a trial-and-error approach to medication selection. 6. "What management is betting on now" Castle Biosciences is focused on expanding the use of its existing tests and developing new ones in areas with significant unmet medical needs. The company aims to deepen the adoption of its core dermatology products by demonstrating their clinical value and ensuring they are integrated into standard medical practice. They are also investing in research and development to create innovative tests that leverage advanced technologies like genomics and spatialomics to provide even more personalized and actionable insights for disease management. The strategy involves building strong clinical evidence and securing reimbursement from insurance providers to ensure their tests become a routine part of patient care.